For thousands of patients worldwide, the promise of new diagnostic criteria for Ehlers-Danlos Syndrome (EDS) has been a beacon of hope—a potential turning point that could finally bridge the gap between their lived reality and clinical recognition. However, the Ehlers-Danlos Society recently announced a significant adjustment to the timeline for these long-awaited updates. As the "Road to 2026" campaign transitions into a 2027 reality, the community finds itself at a crossroads, balancing the frustration of delay with the necessity of scientific precision.
The Delay: A Two-Part Publication Strategy
If the goalposts for the publication of the new diagnostic criteria seem to have moved, the community’s collective perception is correct. The Ehlers-Danlos Society has officially confirmed that the special edition timeline for publication in the American Journal of Medical Genetics has been bifurcated.
Originally anticipated as a unified, comprehensive release, the updated diagnostic criteria for hypermobile EDS (hEDS) and several monogenic variants will now be unveiled in two distinct installments:
- Part 1: Scheduled for publication on December 2, 2026, focusing on the monogenic types of EDS.
- Part 2: Slated for March/April 2027, which will contain the revised criteria for hEDS.
This shift, while administratively logical from a publishing standpoint, has caused palpable anxiety among patients who have been tracking the Society’s countdown for months. Dr. Clair Francomano, a leading voice in the field, addressed the decision by citing the sheer volume and complexity of the data. "There was always too much to put into one publication," she explained. "The decision was made to focus on the monogenic types in the first edition. I hate that this has caused more anxiety for patients, but science is evolving quickly and we want to get this right."
Crucially, the Society has moved to quell fears regarding existing diagnoses. They have issued a clear directive: nobody will lose their diagnosis due to these changes. Clinicians are encouraged to continue utilizing the 2017 criteria until the new standards are officially published and disseminated.
The Scientific Imperative: Why Rigor Matters
In the world of medical research, publication delays are not merely bureaucratic hurdles; they are often the result of the rigorous peer-review process required to ensure that new clinical guidelines are evidence-based and legally defensible. For a community that has spent decades fighting for legitimacy, the stakes are exceptionally high.
The current 2017 criteria have been widely criticized for being "too narrow," focusing primarily on joint hypermobility while ignoring the systemic nature of the condition. Patients often present with a complex constellation of comorbidities—including Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), and various gastrointestinal and neurological manifestations—that the current diagnostic framework fails to fully capture.
As the community looks toward the spring of 2027, the challenge lies in balancing this "multi-systemic" reality with the need for distinct, identifiable clinical markers. The Norris Lab at the Medical University of South Carolina has been at the forefront of this discourse, arguing that future criteria must reflect the systemic nature of hEDS and Hypermobility Spectrum Disorders (HSD) to provide a more accurate picture of patient health.
The Patient Perspective: A Spectrum of Needs
The "EDS community" is not a monolith; it is a collection of distinct groups, each with unique needs and varying expectations for the upcoming changes.
The Quest for Recognition: HSD and hEDS
For those living with HSD, the primary hope is that the new criteria will rectify the clinical confusion created by the 2017 classification. For many, the HSD label has functioned as a "lesser" diagnosis, leading to systemic barriers in care. At the University of Virginia (UVA) EDS Symposium, Ehlers-Danlos Society President Lara Bloom noted that in several European regions, an HSD diagnosis acts as a barrier to receiving insurance coverage or specialized treatment. There is a strong, growing consensus among both researchers and patients that hEDS and HSD exist on a shared spectrum, and many are calling for the two to be blended or more clearly defined to ensure equitable access to care.

The Call for Separation: Rare and Monogenic Types
The conversation takes a different turn for those with rare, monogenic types of EDS, such as Vascular (vEDS), Classical (cEDS), and Kyphoscoliotic EDS. These conditions are confirmed through genetic testing and carry severe, often life-threatening, medical implications.
Abbey Phillipson, founder of The Collagen Advocacy Network, has become a prominent advocate for the "un-bundling" of these conditions. She argues that lumping rare, genetically distinct types under the same broad umbrella as hEDS leads to systemic misdiagnosis and poor outcomes. "Many of us would prefer to be orphaned," Phillipson stated, noting that separate classification could allow these ultra-rare types to qualify for dedicated research funding and specialized clinical focus. Her organization’s surveys suggest that the rare community feels sidelined by the current structure, which often prioritizes the much larger hEDS population at the expense of those with rare, high-risk genetic mutations.
A New Framework: The Rise of "Neuro-EDS"
Amidst the wait for the official criteria, a provocative new concept has emerged that could reshape the clinical approach to EDS: "Neuro-EDS." Introduced by neurosurgeon Dr. Paolo Bolognese and Dr. Allison Bloom, this framework does not suggest a new disease, but rather a new way of categorizing patients based on a neuro-predominant phenotype.
The manuscript, Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders, posits that a significant subgroup of patients exhibits symptoms that are primarily neurological in origin. By grouping patients based on the body systems most severely impacted, proponents believe clinicians could better tailor interventions, especially for those suffering from complex neurological issues like craniocervical instability.
The response from the patient community has been overwhelmingly positive. Disability advocate Karina Sturm notes that this framework could provide a vital lifeline to those frequently dismissed by the medical establishment as having "psychosomatic" illnesses. By giving a formal name to their experience, "Neuro-EDS" could provide the validation necessary to secure treatment in healthcare systems that have historically refused to acknowledge these symptoms.
Implications for the Future
The delay until spring 2027 is undeniably taxing for a community that lives in a state of constant physical and systemic crisis. However, the complexity of the task cannot be overstated. Classifying a systemic disease—one that touches nearly every bodily system—requires a level of consensus that is difficult to achieve in an era of rapidly evolving genetic science.
The implications of these changes will be felt far beyond the pages of the American Journal of Medical Genetics. They will impact:
- Insurance Coverage: Clearer diagnostic criteria are often the key to unlocking treatment coverage.
- Clinical Practice: New nomenclature could reduce the "diagnostic odyssey" that currently sees patients waiting years for an accurate label.
- Research Funding: Proper classification is essential for securing the research dollars needed to develop disease-modifying therapies.
As the EDS community waits, the message from advocates and clinicians alike is one of cautious optimism. While the timeline has shifted, the objective remains the same: to move toward a system that offers not just a label, but a path to better health, clearer validation, and, ultimately, a more standard approach to care.
For the patient, the "Road to 2027" is a long one, but it is a road that—if paved with the right science—may finally lead to the comprehensive, multi-system care that the community has long deserved.
Sources:
- Forghani I, See J, McGonigle WC. "Hypermobile Ehlers–Danlos Syndrome: Diagnostic Challenges and the Role of Genetic Testing." Genes (Basel). 2025 Apr 29;16(5):530.
- Ehlers-Danlos Society, "The Road to 2026/2027" project documentation.
- Collagen Advocacy Network, Patient Sentiment Surveys (2026).
- Bolognese, P., & Bloom, A. (2026). "Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders."
